Breder I, Wolf VLW, Soares AAS, de Carvalho LSF, et al. Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: an active-controlled randomised trial. Diabetes Metab 2021 Nov 19:101304. doi: 10.1016/j.diabet.2021.101304.
PMID: 34808345